FIELD: biochemistry; medicine.
SUBSTANCE: invention relates to biochemistry and medicine and is a peptide of the H[isoD][pS]GYEVHH formula, where the serine residue is phosphorylated, and the aspartic acid residue is isomerized.
EFFECT: this peptide is capable of forming a stable zinc-mediated intermolecular complex with the metal-binding domain of human beta-amyloid and is used to treat Alzheimer's disease.
5 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679080C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
| HAEE PEPTIDE MAGNESIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784746C1 |
| HAEE PEPTIDE ZINC COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784319C1 |
| PEPTIDE CALCIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2785354C1 |
| HAEE PEPTIDE COPPER COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784732C1 |
| AMMONIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784249C1 |
| SODIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784326C1 |
| POTASSIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784425C1 |
| EXOGENIC-INDUCED ANIMAL MODEL OF ALZHEIMER DISEASE | 2012 |
|
RU2532525C2 |
